Spectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company
Spectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company
Home > Product Portfolio > Late Stage > Eflapegrastim

Eflapegrastim

Eflapegrastim Mechanism of action

Fc/G-CSF with flexible PEG linker

Eflapegrastim Mechanism of action

In animal models Fc mediated uptake allowed for higher BM concentrations and higher ANC levels over time vs pegfilgrastim

Eflapegrastim Mechanism of action

In preclinical G-CSF receptor models, G-CSF receptor binding activates downstream signaling and leads to proliferation of neutrophils

Eflapegrastim Mechanism of action

Spectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company

Eflapegrastim is an investigational drug not yet approved by the FDA.

Eflapegrastim is a novel, long-acting Granulocyte-Colony Stimulating Factor (G-CSF) that utilizes a propriety technology.

Development Indications

  • Being evaluated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia

Latest News on eflapegrastim

  • Jun 29, 2018
    Spectrum Pharmaceuticals Presents ADVANCE Phase 3 ROLONTIS® (eflapegrastim) Data at MASCC 2018 and Announces the Phase 3 RECOVER Study Met the Primary Endpoint
    (Click Here for Press Release)
  • Jun 25, 2018
    Spectrum Pharmaceuticals to Host Conference Call Highlighting ROLONTIS® (eflapegrastim) Phase 3 ADVANCE Study Data Presented at Multinational Association of Supportive Care in Cancer (MASCC)
    (Click Here for Press Release)
  • May 16, 2018
    CORRECTING and REPLACING Spectrum Pharmaceuticals Announces Detailed Results from Phase 3 Study of ROLONTIS®(eflapegrastim) Published in an ASCO Abstract
    (Click Here for Press Release)
  • Feb 5, 2018
    Spectrum Pharmaceuticals Announces ROLONTIS™ (eflapegrastim) Met the Primary Endpoint in the Phase 3 ADVANCE Study
    (Click Here for Press Release)
  • Aug 1, 2017
    Spectrum Pharmaceuticals Announces Completion of Enrollment in the Phase 3 Pivotal Study (ADVANCE) of ROLONTIS™ (eflapegrastim), a Novel Long-Acting GCSF
    (Click Here for Press Release)
  • Apr 4, 2017
    Spectrum Pharmaceuticals Highlights Preclinical Data of ROLONTIS™ (eflapegrastim) at the American Association for Cancer Research (AACR) Annual Meeting
    (Click Here for Press Release)
  • Dec 5, 2016
    Spectrum Pharmaceuticals Highlights Five Abstracts on ROLONTIS™ (eflapegrastim) and Poziotinib at the San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Texas, December 6-10, 2016
    (Click Here for Press Release)
  • Jan 29, 2016
    Spectrum Pharmaceuticals Begins Enrolling Patients in Registrational Trial of eflapegrastim, a Novel, Long Acting G-CSF in Patients with Breast Cancer
    (Click Here for Press Release)
  • Dec 16, 2015
    Spectrum Pharmaceuticals Announces Agreement with FDA on the Special Protocol Assessment (SPA) for the Registrational Trial of eflapegrastim, a Novel, Long Acting G-CSF in Patients with Breast Cancer
    (Click Here for Press Release)
  • Dec 8, 2015
    Spectrum Pharmaceuticals Highlights Four Abstracts on eflapegrastim and Poziotinib at the San Antonio Breast Cancer Symposium (SABCS)
    (Click Here for Press Release)
For all Press Releases click here <-->

Back to top